—What are coronavirus symptoms? (opens in new tab)
—How deadly is the new coronavirus? (opens in new tab)
—Is there a cure for COVID-19? (opens in new tab)
—How does coronavirus compare with seasonal flu? (opens in new tab)
—How does the coronavirus spread? (opens in new tab)
—Can people spread the coronavirus after they recover? (opens in new tab)
Young, healthy people are dying of COVID-19 infections, even if most serious cases occur in the elderly and those with preexisting conditions. Now, scientists are looking to see if genes may explain why some people fall seriously ill while others show only mild symptoms, Science magazine reported.
Several ongoing projects aim to analyze and compare the DNA of those with severe COVID-19 infection to those with mild or asymptomatic cases. Differences may lie in genes that instruct human cells to build a receptor called ACE2, which the novel coronavirus relies on to enter cells, Science reported. Alternatively, it may be that genes that support the body's immune response to the virus differ between individuals, or that those with particular blood types carry protective genetic traits that shield them from illness, as suggested by a preliminary study from China.
For now, we don't know which genes might render people susceptible to serious COVID-19 infection, but given the pace of the pandemic, researchers could identify likely candidates within a few months, Andrea Ganna, a geneticist at the University of Helsinki’s Institute for Molecular Medicine Finland (FIMM), told Science.
Related: 10 deadly diseases that hopped across species
Ganna and FIMM Director Mark Daly are heading an international effort to collect genetic data from COVID-19 patients, known as the COVID-19 Host Genetics Initiative. Several biobanks, including FinnGen in Finland and the 50,000-participant biobank at the Icahn School of Medicine at Mount Sinai in New York, have "expressed interest" in contributing data to the study, according to Science. Some groups working with the initiative plan to collect DNA samples from willing patients who are currently hospitalized with COVID-19 infections. Alessandra Renieri, a geneticist at the University of Siena in Italy, expects 11 Italian hospitals to participate in such a study with her own research group.
"It is my opinion that [host] genetic differences are a key factor … for susceptibility to severe acute pneumonia," Renieri told Science. Jean-Laurent Casanova, a pediatrics researcher at the Rockefeller University, is organizing a similar effort within a global network of pediatricians. Their aim is to study "previously healthy" patients under age 50 who have developed severe COVID-19 infections, as their vulnerability to the virus likely lies in their genes, Casanova told Science.
As part of their own initiatives, the UK Biobank will also begin curating data from COVID-19 patients, and the Iceland-based company deCODE Genetics will partner with the country's government to do the same. In the U.S., the Personal Genome Project at Harvard University is recruiting volunteers to share their genetic data, tissue samples, health data and COVID-19 status, Science reported.
In the coming weeks and months, these and other projects may reveal why COVID-19 only triggers a transient cough in some people, while endangering the lives of many others.
- Going viral: 6 new findings about viruses
- The 12 deadliest viruses on Earth
- Top 10 mysterious diseases
Originally published on Live Science.
OFFER: Save at least 53% with our latest magazine deal! (opens in new tab)
With impressive cutaway illustrations that show how things function, and mindblowing photography of the world’s most inspiring spectacles, How It Works (opens in new tab) represents the pinnacle of engaging, factual fun for a mainstream audience keen to keep up with the latest tech and the most impressive phenomena on the planet and beyond. Written and presented in a style that makes even the most complex subjects interesting and easy to understand, How It Works (opens in new tab) is enjoyed by readers of all ages.
Since test kits are caught up and there even antibody versions, we need random sampling to determine exposure levels. Compare exposure levels to hospitalization rates, if high exposure and low hospitalization, release all quarantine from those areas.
Early on it was necessary to ensure that the lethal/requiring care varieties were contained and the mild/asymptomatic allowed to spread. Given the increasing rates of positive tests and low hospitalization in most areas i think we're there.